Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Actinium Pharmaceuticals, Inc.

  • Sandesh Seth, Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC’s or Antibody Radiation Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium’s pipeline of clinical-stage targeted conditioning ARCs target the antigens CD45 and CD33 for patients with a broad range of hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute lymphoblastic leukemia (ALL), Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.

  • Date:Monday, February 11
  • Time:2:15 PM - 2:30 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23266
  • Goal for Presentation:Expand investor base
  • Company Website:www.actiniumpharma.com
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Market Cap:75,000,000
  • Ticker:ATNM
  • Exchange:NYSE AMERICAN
  • CEO/Top Company Official:Sandesh Seth
  • Year Founded:2000
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Iomab-B
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Speakers
Sandesh Seth
Actinium Pharmaceuticals, Inc.
Back